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Stromal cells in adipose tissue are useful for repair/regenerative therapy as they harbor a 
substantial number of mesenchymal stem cells; therefore, freshly isolated autologous 
uncultured adipose tissue-derived stromal cells (u-ADSCs) are useful for regenerative 
therapy, and obviate the need for mesenchymal stem cells. We evaluated the therapeutic 
effect of murine u-ADSCs and the sorted subsets of u-ADSCs in a concanavalin A (ConA)-
induced murine model of hepatitis, as well as their characteristics. We found that 10% to 20% 
of u-ADSCs expressed the CD45 leukocyte-related antigen. CD68, which is a marker of 
macrophages, was expressed by 50% of CD45+ u-ADSCs. About 90% of CD68+CD45+ cells 
expressed CD206 antigen, which is a marker of inhibitory M2-type macrophages. Genes 
related to M2-type macrophages were more highly expressed by CD45+, especially 
CD45+/CD206+, than by CD45− u-ADSCs. CD45+ u-ADSCs inhibited the expression of 
cytokines/chemokines and suppressed the proliferation of splenocytes stimulated with ConA. 
We observed that not only whole u-ADSCs, but also the CD45+ subset of u-ADSCs 
ameliorated the ConA-induced hepatitis in mice. In conclusion, freshly isolated murine u-
ADSCs were effective against acute hepatitis, and CD45+ u-ADSCs, phenotypically and 





 Repair/regenerative therapy of impaired organs using stem cells has been a focus of 
research, while stem cells themselves have also been investigated intensively [1]–[3]. Various 
stem cell types have been discovered, for example, toti-potent stem cells, such as embryonic 
stem (ES) cells and induced pluripotent stem cells (iPS cells), and somatic stem cells, 
including tissue-resident stem cells and multi-potent mesenchymal stem cells (MSCs). MSCs 
are the ideal stem cells as they naturally reside in the adult body. In addition, they inhibit the 
immune system, which facilitates the repair and restoration of organs damaged by 
inflammation [4]–[6]. Bone marrow and adipose tissue are useful for repair/regenerative 
therapy as a feasible autologous source, since stromal cells in these tissues are naturally 
enriched in MSCs, avoiding advanced techniques for obtaining stem cells as of induced 
pluripotent stem cells [7],[8] and are not associated with serious ethical issues, such as the 
destruction of embryos for the establishment of ES cells. Subcutaneous adipose tissue is an 
attractive source of MSCs; adipose tissue contains approximately 100-fold more MSCs than 
bone marrow [9],[10]. In addition, subcutaneous adipose tissue is readily accessible to the 
aspiration of stromal cells enriched with MSCs [10]. Thus, freshly isolated stromal cells are 
useful for the repair/regenerative therapy of damaged tissue [11]–[13]. 
 Non-clinical [14] and clinical studies using freshly isolated bone marrow and adipose 
tissue-derived stromal cells for the therapy of impaired organs have been reported [15]–[17]. 
Stromal cells from bone marrow and adipose tissues contain a substantial number of MSCs 
and a heterogeneous cellular composition—adipose tissue contains not only MSCs but also 
fibroblasts, endothelial cells, and leukocytes, among others [18],[19]. Analysis of 
subfractions of freshly isolated and uncultured adipose tissue-derived stromal cells (u-
ADSCs) would enable determination of their biological characteristics. 
 In the current study, u-ADSCs and the subsets of them, CD45+ u-ADSCs and CD45– 
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u-ADSCs, ameliorated concanavalin A (ConA)-induced damage to murine liver tissue. By 
analyzing surface antigen expression, we found that among the CD45+ subset of u-ADSCs, 
half of them were phenotypically similar to M2-type macrophages. This was confirmed by 
gene expression profile data and suppressive effect against proliferation of ConA-stimulated 
splenocytes in vitro. Thus, the immunosuppressant effect of treatment of inflamed tissues 




Characteristics of u-ADSCs  
Stromal cells were isolated from the inguinal adipose tissue of C57BL/6J mice. The 
expression of surface antigens by u-ADSCs and cultured adipose tissue-derived stem cells (c-
ADSCs) obtained by the expansion of u-ADSCs was determined. The u-ADSCs contained a 
higher frequency of cells expressing CD45 (10% to 20%) and CD31 (56.6%) than did c-
ADSCs. In addition, u-ADSCs harbored cells expressing CD29 (35.5%), CD44 (47.3%), and 
CD90 (25.3%), confirming the presence of MSCs antigens; after culturing, the frequency of 
these antigens in c-ADSCs became highly expressed: CD29 (98.3%), CD44 (93.8%), and 
CD90 (77.1%) (Fig. 1A, B). The average sizes of the u-ADSCs and c-ADSCs were 11.3 ± 4.0 
µm (SD) (n = 1868) and 27.6 ± 7.9 µm (SD) (n = 533), respectively (Fig. 1C).  
 
Therapeutic effect of u-ADSC, CD45+ u-ADSCs and CD45– u-ADSCs in ConA hepatitis 
mice 
We previously reported that cultured and expanded c-ADSCs were effective in 
murine ConA hepatitis [20]. Thus, we determined the effect on ConA hepatitis of freshly 
isolated u-ADSCs, the source of c-ADSCs, as well as the u-ADSCs subsets which were 
enriched by using FACS (Supplemental fig. 1). The u-ADSCs, CD45+ u-ADSCs, CD45– u-
ADSCs, c-ADSCs and SPCs (control) were administered via the tail vein 3 h after ConA 
injection. Sixteen hours after ConA administration, liver tissues and sera were assessed. In 
terms of macroscopic appearance, livers were more intact in mice treated with u-ADSCs, 
CD45+ u-ADSCs, CD45– u-ADSCs or c-ADSCs compared to the control group; consistently, 
upon microscopic observation, the liver tissues in the above mentioned groups showed no 
evidence of necrosis (data not shown). The u-ADSC, CD45+ u-ADSCs and CD45– u-ADSCs 
treatments inhibited the ConA-induced infiltration of immune-mediating CD11b+, Gr-1+ and 
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F4/80+ cells (Fig. 2A, B); no difference was detected with regard to the infiltration of CD4+ or 
CD8+ T cells in the livers between treatments. The serum ALT, and LDH activity levels were 
lower in the u-ADSCs, CD45+ u-ADSCs, CD45– u-ADSCs and in c-ADSCs treatment groups 
than in SPCs (control group) (Fig. 2C). We also measured the cytokine concentration in the 
same sera. No significant difference of IFNg and TNF concentration was shown in any 
groups; however immunosuppressive cytokine, IL-10, tended to be slightly increased in the 
CD45+ u-ADSC treatment group (Supplemental Fig. 2A). Instead, we observed significant 
decrease of Ifng and increase of Il10 expression in the liver tissues of ConA hepatitis mice 
which were treated with CD45+ u-ADSCs (Supplemental Fig. 2B). 
 
CD45+ u-ADSCs have a M2 macrophage-like phenotype 
Freshly isolated u-ADSCs were effective against ConA hepatitis due to their 
immunosuppressive effect. We also found that the subset expressing CD45, leukocyte lineage 
antigen, were effective. To characterize the CD45+ subset of u-ADSCs in details, we firstly 
compared the antigen-phenotypic features of the CD45+ fraction with those of the CD45+ 
fractions of peripheral blood cells (PBCs), splenocytes (SPCs), and bone marrow cells 
(BMCs) (Fig. 3A, B). Of the CD45+ u-ADSCs, 50% expressed CD68 (Fig. 3B), suggestive of 
a macrophage phenotype [21], and almost 90% of them co-expressed CD206, suggestive of 
an M2 phenotype  [22]–[24] (Fig. 3D). Furthermore, u-ADSCs, c-ADSCs, and the FACS 
sorted CD45+ PBCs, CD45+ SPCs, CD45+ uADSCs, CD45− u-ADSCs, CD45+/CD206+ u-
ADSCs, CD45+/CD206− u-ADSCs, CD45+/CD68+ u-ADSCs, CD45+/CD68− u-ADSCs 
fractions were assessed for the expression of genes related to M1- and M2-type macrophages 
by real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The 
expression of genes associated with M1-type macrophages—Il1b, Tnf, Il23a, Cd80, Il6, 
Nos2, Il12a, and Il12b—was downregulated in CD45+ u-ADSCs compared with that in 
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CD45+ PBCs and SPCs (Fig. 4A). In contrast, most M2-type genes (Retnla, Arg1, Mrc1, 
Ccl22 and Ccl24) were upregulated in CD45+ u-ADSCs (Fig. 4B). Among the subsets of 
CD45+ u-ADSCs, only the CD45+/CD206+ u-ADSCs highly expressed the M2-type genes, 
not CD45+/CD206− u-ADSCs, CD45+/CD68+ u-ADSCs, or CD45+/CD68− u-ADSCs. The 
gene expression profile of c-ADSCs were not indicative of M2 macrophage. 
 
Gene expression profile of CD45+ and CD45− u-ADSCs  
CD45+ and CD45− u-ADSCs were subjected to gene expression analysis. A total of 
8086 genes with a fold change > 4 (P-value <0.01, variance >2.6) were identified (Fig. 5A), 
of them, 2884 genes were upregulated and 3838 were downregulated in CD45+ u-ADSCs 
compared with their expression levels in CD45− u-ADSCs. Pathway enrichment analysis 
(Fig. 5B) and biological process enrichment analysis (Fig. 5C) of these genes showed that 
CD45+ u-ADSCs were related to activation and regulation of the immune response, 
regulation of leukocyte-mediated immunity, and cytokine/chemokine signaling pathways. In 
contrast, the CD45− fraction was related to developmental and morphogenic activation, cell 
matrix organization, ECM-receptor interactions, and structure organization (Fig. 5B, C). The 
expression of genes representative of M1- or M2-type macrophages was also evaluated; M1-
macrophage-related genes were downregulated in CD45+ u-ADSCs (Fig. 6A), and murine 
M2-macrophage specific genes were upregulated [23] (Fig. 6B).  
 
CD45+ u-ADSCs, and CD45+/CD206+ u-ADSCs suppressed activated SPCs in vitro 
To assess the immune-modulatory function of CD45+ u-ADSCs, freshly isolated 
splenocytes were co-cultured with CD45+ u-ADSCs or total u-ADSCs in medium containing 
ConA. Two hours later, splenocytes in the culture insert were collected, and subjected to 
RNA isolation and gene expression analysis by qRT-PCR. The u-ADSCs significantly 
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suppressed the expression of Ccl3 (Fig. 7A) and Tnf (Fig. 7C); in addition, CD45+ u-ADSCs 
suppressed the expression of not only Ccl3 (Fig. 7A) and Tnf (Fig. 7C), but also Ifng (Fig. 
7B) by splenocytes. We also performed [3H]-Thymidine incorporation assay; irradiated 
CD45+ u-ADSCs or CD45+/CD206+ u-ADSCs were co-cultured with ConA-stimulated 
splenocytes for 24 hours, followed by 16 hours of pulsing with [3H]-Thymidine; then the 
extent of [3H]-Thymidine incorporation was measured by radioactivity counter. The CD45+ 
subset of u-ADSCs and the CD45+/CD206+ fraction suppressed the proliferation of 
splenocytes stimulated with ConA (Fig. 7D). 
 
IL-10-producing ability of u-ADSCs, CD45+, and CD45+/CD206+ of u-ADSCs. 
IL-10 is the important cytokine produced by M2 macrophage. Therefore, we assessed 
Il10 expression of u-ADSC and their subsets under basal and activation conditions by gene 
expression analysis, as well as the frequency of cells which were intracellularly stained for 
IL-10 assessed by flow cytometry. Freshly isolated u-ADSCs, CD45+ u-ADSCs, CD45– u-
ADSCs were stimulated with IL-4/IL-13 or lipopolysaccharides (LPS), for 40 hours followed 
by assessment of Il10 gene expression by qRT-PCR. The whole u-ADSCs and CD45+ u-
ADSCs greatly expressed Il10 in both IL-4/IL-13, and LPS-stimulated conditions, 
respectively, as well as in basal condition (Supplemental Fig. 3A); the CD45– u-ADSCs did 
not express detectable level of Il10 by qRT-PCR. Next, we performed intracellular staining 
assay of IL-10. The freshly isolated u-ADSCs were cultured with IL-4/IL-13, or LPS; then, 
FACS analysis of cells co-stained with FITC anti-CD45, PE anti-CD206 and Alexa Fluor® 
647 anti-IL10 antibodies were performed (Supplemental Fig. 3B). Frequencies of IL-10 
expressing cells of the u-ADSCs under the basal condition, IL-4/IL-13 or LPS stimulant were 
7.5%, 7.4% and 8.4%, respectively. The frequency of IL-10 expressing cells in CD45+ u-
ADSCs (8.4%) was slightly higher compared to CD45– u-ADSCs (7.2%) under basal 
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condition; when cells were cultured with stimulants, either IL4/IL-13 or LPS, the frequency 
of IL-10 expressing cells in the CD45+ subset resulted in 10.6% by IL4/IL-13 and 10.7% by 
LPS, respectively; in contrast, the frequency of IL-10 expressing cells in CD45− u-ADSCs 
did not increase (5.4%, and 6.6% by IL-4/IL-13 and LPS stimulation, respectively). The IL-
10 expressing cells of the CD45+/CD206+ u-ADSCs subset were 20.1% in basal condition, 
32.6% with IL-4/IL-13, and 24.4% with LPS; these high IL-10 expressing frequencies further 
confirmed the M2-like character of this CD45+/CD206+ u-ADSCs subset. On the contrary, 





Stromal cells of adipose tissue and bone marrow have potential for repair/regenerative 
therapy as they harbor pluripotent and immunosuppressive MSCs. Repair/regenerative 
therapy using cells freshly isolated from these tissues is preferable, as they are accessible and 
complicated procedures are not required to obtain cells enriched with MSCs. In the current 
study, we observed that u-ADSCs were therapeutically beneficial to hepatitis as c-ADSCs 
were [20], and a part of its mechanism was contributed by the CD45+ subset of u-ADSCs; 
although the CD45− subset of u-ADSCs were also proven to contribute to therapeutic effect 
of u-ADSCs.  We found that 10–20% of u-ADSCs expressed the CD45+ leukocyte-related 
antigen, and the majority were phenotypically similar to macrophages, particularly M2 
macrophages, in terms of surface antigen expression and gene expression profile; they were 
functionally immunosuppressive in vitro and in vivo, suggesting that they contributed to the 
therapeutic effects of u-ADSCs. 
Stromal cells freshly isolated from adipose tissue include not only MSCs but also 
inflammatory cells, fibroblasts, and endothelial cells, among others [18],[19]. Thus, 
investigations should determine the cell types present and the suitability of their biological 
characteristics for repair/regenerative therapy. The majority of CD45+ u-ADSCs was 
phenotypically similar to macrophages, specifically M2-type macrophages, which express 
CD206. Indeed, their upregulated expression of Retnla, Egr2, Arg1, Mrc1, Ccl17, and Ccl22 
supports their similarity to immune-suppressive M2-type macrophages [22],[23],[25]. 
Functionally, these M2-macrophage-like cells suppressed splenocytes stimulated by ConA in 
vitro, expressed high level of IL-10, and showed immunosuppressive activity in a murine 
model of inflammation-related liver damage in vivo. Thus, inhibitory inflammatory cells, 
specifically those similar to M2-type macrophages, are present among CD45+ u-ADSCs from 
enzymatically digested adipose tissue. A previous phenotypic analysis of human adipose 
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tissue-derived stromal cells showed that hematopoietic stem cells harbored M2-like anti-
inflammatory cells, and were likely derived from myeloid tissue [26]. We functionally 
identified inhibitory inflammatory cells among leukocyte-related-antigen-expressing u-
ADSCs. Moreover, macrophages obtained from murine bone marrow are useful for the 
treatment of inflammation and fibrosis, and for liver regeneration, in an animal model [27], as 
was the CD45+ fraction in this study. Although macrophages have diverse biological 
characteristics [28], their fraction has been shown to be critically involved in repair, tissue 
development, and homeostasis [29].   
We previously observed that ConA hepatitis was mediated by monocyte/macrophage 
lineage cells and CD4+ T cells in part [20]. In the current study, we observed that infiltration 
of CD11b+ cells in the liver of ConA hepatitis were decreased, but not CD4+ T cells. 
However, T cell-related cytokines such as IL-10 and IFNg expression in the liver of ConA 
hepatitis mice treated with CD45+ u-ADSCs were increased and decreased, respectively, 
implying that it is possible that CD4+ T cells were functionally affected by CD45+ u-ADSCs 
treatment. The details on how u-ADSCs and their subsets are immune-suppressive to ConA 
hepatitis should be further investigated. About half of CD45+ u-ADSCs were not 
phenotypically macrophage in the context of surface antigen expression as well as gene 
expression profile. The biological characteristics of these “non-macrophage” CD45+ u-
ADSCs should be further investigated on how they contribute to immune-suppression to 
ConA hepatitis mice in vivo. Furthermore, the subset CD45− of u-ADSCs were also 
therapeutically effective to acute hepatitis, and they should be explored, especially in the 
context of the fraction containing mesenchymal stem cells which are immune-suppressive to 
inflammation.  
 In conclusion, the entire u-ADSC population can be used to treat damaged tissue 
[18],[30]–[36]; they contain a substantial number of MSCs and they enable the repair and 
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restoration of inflammation-mediated liver damage. These cells include an immune-
suppressive macrophage-phenotype subfraction, which contributes to amelioration of 
inflammation-mediated tissue damage. Freshly isolated u-ADSCs are advantageous 
compared to c-ADSCs, since they do not require manufacturing process or culture; these 
factors presumably facilitate the application to clinical use [37],[38]. Thus, adipose-tissue-






















Materials and Methods 
Stromal cell isolation from murine inguinal subcutaneous adipose tissue 
The inguinal adipose tissues of C57BL/6J male mice (12 to 16 weeks old) (Charles 
River Laboratories Japan, Yokohama, Japan) were digested using type I collagenase 
(Worthington Biochemical Corporation, Lakewood, NJ, USA).  The stromal fraction was 
separated from adipocytes and fat-derived debris by centrifugation (350 g for 15 min); the 
supernatant was then discarded. As described previously [20], c-ADSCs were obtained by 
culturing u-ADSCs in medium comprising a 1:1 ratio of DMEM/F12 (Gibco, Life 
Technologies, Carlsbad, CA, USA) supplemented with 20% v/v heat-inactivated fetal bovine 
serum (Life Technologies) and 1% antibiotic–antimycotic solution (Life Technologies); the 
c-ADSCs were passaged five times and used for experiments. Our institutional review board 
approved the procedures for the care and use of laboratory animals in this study. 
 
Isolation of splenocytes, peripheral blood cells, and bone marrow cells 
Murine SPCs were isolated from C57BL/6J male mice as described previously [39]. 
To isolate PBCs, blood was withdrawn from anesthetized male C57BL/6J mice by cardiac 
puncture, placed in a heparin sodium vacutainer (Venoject II, VP-H100K; Terumo, Tokyo, 
Japan), diluted with an identical volume of PBS (Wako Pure Chemical Industries, Osaka, 
Japan), filtered through a 40 µm cell strainer (Corning Life Sciences, Durham, NC, USA), 
and centrifuged. Red blood cells were then lysed in ACK Lysing Buffer (Lonza, 
Walkersville, MD, USA) and the supernatant was discarded. Bone marrow cells (BMCs) 
were extracted from the femoral bone of male C57BL/6J mice. 
 
Flow cytometry  
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Freshly extracted u-ADSCs or c-ADSCs were incubated in PBS supplemented with 
2% v/v FBS (Gibco, Life Technologies) for 10 min at 4C with murine FcR Blocking 
Reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cells were then washed, 
incubated with fluorescence-labeled antibodies, and analyzed using a FACSCalibur® 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The following antibodies were used: 
FITC-labeled rat anti-mouse CD45 (clone 30-F11) (BD Pharmingen, San Jose, CA, USA), 
PE-anti-mouse CD34 (clone HM34), PerCP/Cy5.5-anti-mouse CD68 (clone FA-11), APC-
anti-mouse CD206 (MMR) (clone C068C2) (Biolegend, San Diego, CA, USA), FITC-
hamster anti-rat CD29 (clone Ha2/5) (BD Pharmingen), PE-anti-mouse CD73 (clone 
TY/11.8) (Biolegend), FITC-anti-human/mouse CD44 (clone IM7) (eBioscience, San Diego, 
CA, USA), PE-anti-mouse CD105 (clone MJ7/18) (Miltenyi Biotec, Tokyo, Japan), PE-anti-
mouse CD31 (clone 390) (Beckman Coulter, Brea, CA, USA), and PE-anti-mouse CD90 
(clone G7) (Novus Biologicals, Littleton, CO, USA). Data were analyzed using FlowJo® V10 
software (Tree Star, Ashland, OR, USA). 
 
Cell size characterization 
Micrographs of u-ADSCs and c-ADSCs in suspension were obtained and analyzed 
using ImageJ software (NIH, Bethesda, MD, USA) [40]. 
 
Cell sorting 
Freshly isolated u-ADSCs, PBCs, or SPCs were filtered through a 100 µm mesh 
(Corning Life Sciences, Durham, NC, USA) and then through a 40 µm cell strainer, and 
suspended in sorting buffer: PBS supplemented with 2% w/v bovine serum albumin (Sigma-
Aldrich, St. Louis, MO, USA), 25 mM HEPES (Dojindo Molecular Technologies, Inc., 
Kumamoto, Japan), and 5 mM EDTA (Nippon Gene Co., Tokyo, Japan). Cells were 
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centrifuged and the supernatant aspirated. The obtained cells were incubated with murine 
FcR Blocking Reagent (Miltenyi Biotec) for 10 min at 4C, washed, and incubated for a 
further 10 min at 4C with FITC-labeled rat anti-mouse CD45 and 7-amino-actinomycin D 
(BD Biosciences). The labeled cells were sorted using a FACS ARIA II® cytometer (BD 
Biosciences) (Supplemental Fig. 1). 
 
Treatment of acute ConA-induced hepatitis with u-ADSCs, CD45+ u-ADSCs or CD45− u-
ADSCs  
C57Bl/6J male mice (24 weeks old) were injected with ConA (20 mg/kg) (Wako) in 
PBS (200 µl) via the tail vein, as described previously [20]. Three hours later, 7.5  105 cells 
were injected in a volume of 100 µl of PBS into the tail vein for each treatment groups: u-
ADSCs, CD45+ u-ADSCs, CD45– u-ADSCs and SPCs (control). For the c-ADSCs treatment 
group, the injected cells were fixed to 1  105 cells in order to avoid thromboembolism. 
Sixteen hours later, the mice were euthanized, and blood sera and liver tissues were sampled. 
 
Histological and immunohistochemical analyses 
Liver tissue was fixed in IHC Zinc Fixative® (BD Pharmingen) for paraffin 
embedding. Tissue sectioning, deparaffinization, epitope retrieval, and peroxidase and protein 
blockings were performed as described previously [20]. Rat anti-mouse CD4 (clone 
H129.19), CD8a (clone 53-6.7), CD11b (clone M1/70), Gr-1 (clone RB6-8C5) (BD 
Pharmingen), F4/80 (clone BM8) (Invitrogen, Life Technologies, Camarillo, CA, USA) and 
primary antibodies were used. Tissues were incubated with the primary antibodies in PBS 
containing 1% BSA and stored overnight at 4°C. After washing in PBS, the anti-rat detection 
reagent Histofine Simple Stain Mouse MAX PO® (Nichirei Corporation, Tokyo, Japan) was 
applied, followed by incubation for 30 min at room temperature. Hydrogen peroxide solution 
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containing imidazole-HCl buffer was then applied, followed by 3,3′-diaminobenzidine 
substrate solution (Dako ChemMate EnVision Kit / HRP (DAB)®) (Dako, Kyoto, Japan) to 
visualize immune complexes; finally, hematoxylin was applied as a counterstain. 
 
Co-culture of ConA-stimulated splenocytes with u-ADSCs 
SPCs isolated from C57BL/6J male mice were suspended in medium composed of 
RPMI 1640 (Gibco, Life Technologies), 10% v/v heat-inactivated FBS, and 10 µg/ml ConA, 
and plated in 24-well plates at 2.44  106 cells/ml in triplicate (3  105 cells/well) (BD 
Falcon). Suspensions of u-ADSCs or CD45+ u-ADSCs (5  105 cells/well) were placed in 
culture insert wells (BD Falcon Cell Culture Inserts) and co-cultured with SPCs. Two hours 
later, the inserts harboring u-ADSCs or fractioned cells were removed, and SPCs were lysed 
for RNA extraction. 
 
[3H]-Thymidine incorporation assay 
SPCs (5  105 cells) were co-seeded in a 96 well plate-round bottom with either 3  
105 irradiated (5000 rad) u-ADSCs or irradiated (5000 rad) u-ADSCs subsets in triplicates. 
RPMI complete medium (150 µl) was used with or without ConA as stimulant (5 µg/mL); 
then, incubated for 24 h at 37°C, followed by pulsing with 1 µCi/well of [3H]-Thymidine for 
16 h. Cells were harvested by centrifugation and were washed twice with PBS. The harvested 
cells were suspended in Clear-sol I® liquid scintillation (Nacalai Tesque, Kyoto, Japan) and 
radioactivity was quantified with the LSC-5100® liquid scintillation counter (Aloka, Tokyo, 
Japan). 
 
Activation of u-ADSCs by stimulants for macrophage subsets and intracellular staining 
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Freshly isolated u-ADSCs, CD45+ u-ADSCs and CD45–  u-ADSCs (3 x 105 cells) 
were seeded in triplicates and cultured for 40 hours with, (i) 20 ng/mL of recombinant murine 
IL-4 (PeproTech, NJ, USA) plus 20 ng/mL of recombinant murine IL-13 (R&D Systems, 
MN, USA), (ii) 50 ng/mL of LPS (Sigma-Aldrich), or (iii) kept in RPMI1640 culture media 
without any stimulants as basal condition; cells were lysed for RNA isolation, and the 
expression of Il10 was assessed by qRT-PCR. For assessing the frequency of the IL-10 
expressing cells for each subset, 1 x 106 freshly isolated u-ADSCs were seeded in triplicates 
and cultured, as above mentioned, for 40 hours with IL-4/IL-13, LPS or, kept in basal 
condition. Cells were harvested, co-stained with FITC anti-CD45 and PE anti-CD206, 
followed by fixation, permeabilization, and incubated with Alexa Fluor® 647 anti-IL10 (clone 
JES5-16E3) (Biolegend) using Inside Stain Kit® (Miltenyi Biotec); FACS data was collected 
with the BD Accuri™ C6 Cytometer (BD Biosciences), the frequency of IL-10-stained cells 
was quantified by FACS analysis. 
 
Serologic analysis and serum cytokine concentrations measurement 
Blood was collected from mice from the venous plexus in the retro-orbital space, 
serum was separated from clotted blood by centrifugation, ALT and LDH activities were 
measured as described previously [20]. The same sera was also used for assessing the 
concentrations of cytokines by using the Bio-Plex Pro™ cytokine assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) following the manufacturer’s protocol.  
 
Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
A High Pure RNA Isolation Kit® (Roche Diagnostics GmbH, Mannheim, Germany) 
was used for total RNA purification as per the manufacturer’s protocol. Single-stranded 
cDNA was synthesized from RNA using reverse transcriptase (Applied Biosystems, 
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Waltham, MA, USA) following the supplier’s protocol. Real-time qPCR was performed with 
the Applied Biosystems® 7900HT Fast Real-Time PCR System instrument following the 
manufacturer’s protocol. cDNA was mixed with qPCR MasterMix Plus® (Eurogentec, 
Seraing, Belgium) and the following hydrolysis TaqMan® Gene Expression Assay probes 
(Applied Biosystems): Tnf, Ifng, Ccl3, Il1b, Ccl2, Cxcl10, Il6, Nos2, Il12a, Il12b, Il23a, 
Cd80, Mrc1, Cd163, Retnla, Arg1, Il10, Ccl22, and Ccl24. 
 
DNA microarray analysis 
RNAs were isolated, amplified, and labeled with Cy3 using a Quick Amp Labeling 
Kit following the manufacturer’s protocol (Agilent Technologies, Santa Clara, CA, USA). 
Complementary RNA was hybridized on a Whole Mouse Genome 4 × 44K Array (Agilent 
Technologies). A DNA microarray scanner (model G2505B, Agilent Technologies) was used 
to read microarrays. Gene expression analysis was performed using the BRB array tool 
(http://linus.nci.nih.gov/BRB-ArrayTools.html), quantile normalization was applied. Data are 
from one test per cell population; gene pool subsets were selected based on the canonical M1 
and M2 macrophage gene signatures, and newly identified murine genes in the Gene 
Expression Omnibus NCBI database (GSE69607) [23]. Comprehensive functional analysis of 




Data are expressed as means ± SD, unless stated otherwise. OriginPro 8 SR0 
(v8.0724; OriginLab Corporation, Northampton, MA, USA) was used for graphing and data 
analysis. GraphPad was used for unpaired two-tailed t-test (http://graphpad.com/quickcalcs/, 
GraphPad Software, La Jolla, CA, USA), R package was used for the Kruskal-Wallis test and 
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R package Pairwise Multiple Comparison of Mean Ranks Package (PMCMR) for the post-
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FIGURE 1. Characteristics of u-ADSCs and c-ADSCs. 
Freshly isolated u-ADSCs were obtained by digestion of the inguinal adipose tissue of 
C57BL/6J male mice, and were cultured to expand c-ADSCs. (A) Scattergrams of flow 
cytometry analysis of cells using fluorescence-conjugated antibodies to surface antigens. The 
data are representative of three independent experiments. (B) Frequency of u-ADSCs and c-
ADSCs expressing surface markers. The data are representative of three independent 
experiments. Bars: SD. (C) The size distribution of u-ADSCs and c-ADSCs at passage 5 was 
assessed using ImageJ; relative FSC/SSC scatterplots are shown. The average sizes of u-
ADSCs and c-ADSCs were 11.2 ± 4.0 µm (SD) (n = 1868) and 27.6 ± 7.9 µm (SD) (n = 
533). 
 
FIGURE 2. Therapeutic effect of u-ADSC administration in ConA hepatitis mice. 
C57Bl/6J male mice were injected with ConA (20 mg/kg). Three hours later, the u-ADSCs, 
CD45+ u-ADSCs, CD45– u-ADSCs, c-ADSCs or SPCs (control), were injected into the tail 
vein. Sixteen hours after the ConA injection, the mice were euthanized, and liver tissues and 
blood sera samples were obtained. (A) Immunohistochemical analysis of inflammatory cell 
markers (CD4, CD8, CD11b, Gr-1, F4/80) in liver tissue. One representative stain image of 
each group is presented. Magnification: ×100. Scale bars: 100 μm. The brown-stain of the 
inflammatory cells in the tissue sections (A) was quantified by using the colour 
deconvolution option of ImageJ (B); black bar: u-ADSCs treatment group; oblique line bar: 
CD45+ u-ADSCs treatment group; diagonally hatched bar: CD45− u-ADSCs treatment group; 
dark gray/horizontal line bar: c-ADSCs treatment group; white/hatched bar: SPCs treatment 
group; (representative area analyzed = 1.576 mm2). (C) At 16 h after ConA administration, 
serum ALT, and LDH activities were lower in the u-ADSC, CD45+ u-ADSC, CD45− u-
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ADSC and c-ADSC treatment groups than in the control group. Kruskal Wallis rank sum test 
followed by the Conover post hoc test was performed as statistical analysis. *P<0.05, 
**P<0.01; Treatment replicates: u-ADSC (n=6), CD45+ u-ADSC (n=6), CD45− u-ADSC 
(n=4), c-ADSC (n=5) and SPCs (n=6). 
 
FIGURE 3. Characteristics of the CD45+ u-ADSCs. 
The u-ADSCs, PBCs, SPCs, and BMCs were stained with the indicated antibodies and 
subjected to FACS analysis. (A) Frequency of CD45+ u-ADSCs, compared with those of 
PBCs, SPCs, and BMCs. (B) Frequency of cells expressing surface markers of macrophages 
and MSCs among CD45+ u-ADSCs, PBCs, SPCs, and BMCs. (A, B) Bars: SD. (C, D) 
Phenotypic characteristics of CD45+ u-ADSCs. (C) Scattergram of FSCs and SSCs among 
the u-ADSCs. (D) Frequency of u-ADSCs expressing CD45 and CD68, and that of CD206-
expressing CD45+CD68+ u-ADSCs. (A–D) All results are representative of two independent 
experiments. 
 
FIGURE 4. Expression of M2-type macrophage-related genes in u-ADSCs and subsets. 
The expression of genes representative of M1- or M2-type macrophages was assessed by 
qRT-PCR in freshly isolated cell populations. (A) Expression of M1-macrophage-related 
genes. (B) Expression of M2-macrophage-related genes. Figure abbreviations: PBC: CD45+ 
PBCs; SPC: CD45+ SPCs; CD45pos: CD45+ uADSCs; CD45neg: CD45− u-ADSCs; CD206pos: 
CD45+/CD206+ u-ADSCs; CD206neg: CD45+/CD206− u-ADSCs; CD68pos: CD45+/CD68+ u-
ADSCs; CD68neg: CD45+/CD68− u-ADSCs. Y-axis represents the relative gene expression 




FIGURE 5. Biological process and pathway enrichment analysis of genes expressed by 
CD45+ and CD45− u-ADSCs. 
Gene expression analysis of CD45+ and CD45− u-ADSCs was performed using DNA 
microarrays. (A) Scatterplot of fourfold upregulated and downregulated genes (P < 0.01, 
variance > 2.6) in CD45+ u-ADSCs compared with CD45− u-ADSCs. Light gray line, 
fourfold change. The biological characteristics of the upregulated and downregulated genes 
were annotated and processed using DAVID Bioinformatics Resources 6.7. Pathway 
enrichment analysis (B) and biological process enrichment analysis (C) were conducted for 
genes upregulated in CD45+ u-ADSCs compared with CD45− u-ADSCs (right-facing bars), 
and vice versa (left-facing bars). Bars represent −log(P-values); P-values were calculated by 
hypergeometric test (B, C). 
  
FIGURE 6. Heatmap analysis of the expression of M1- and M2-type macrophage-related 
genes in CD45+ u-ADSCs compared with that in control cells (CD45− u-ADSCs, PBCs, and 
SPCs) by DNA microarray. (A) M1-macrophage-related genes. (B) M2-macrophage-related 
genes. The data are from one test per cell population. 
 
FIGURE 7. Immunosuppressive effects of CD45+ u-ADSCs on activated splenocytes in 
vitro. 
Freshly isolated splenocytes were co-cultured with total u-ADSCs or only CD45+ u-ADSCs 
on culture inserts in medium containing ConA. Two hours later, the splenocytes were 
collected and subjected to RNA isolation and gene expression analysis by qRT-PCR. (A) 
Ccl3, (B) Ifng, (C) Tnf. A two-tailed t-test was used for statistical analysis. The data are 
representative of three independent experiments. (D) 5 x 105 SPCs were co-seeded with 3 x 
105 irradiated u-ADSCs, CD45+ u-ADSCs, or CD45+/CD206+ u-ADSCs in triplicates under 
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ConA stimulation; cells were co-cultured for 24 hours followed by 16 hours of pulsing with 
[3H]-Thymidine; cells were harvested and radioactivity quantified. H-DPM: [3H]-
disintegrations per minute; n=3. Student t-test was performed. (A-D) *P<0.05, **P<0.01, 
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